SCHEMBL3016691

SCHEMBL3016691

Cc1cc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4ccccc4Br)CC3)n2)c(C)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 3/20 0.42
LMNA P02545 3/20 0.41
KMT2A Q03164 3/20 0.41
MEN1 O00255 2/20 0.41
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
PKM P14618 1/20 0.39
TP53 P04637 1/20 0.39
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
KDM4E B2RXH2 1/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
RAB9A P51151 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008342 0.92 LMNA (0.44) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3001890 0.89 GBA1 (0.42) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3014938 0.89 CHRM4 (0.43) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3008380 0.87 ALDH1A1 (0.42) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3014384 0.86 GBA1 (0.43) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3009631 0.86 GBA1 (0.43) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3015945 0.86 KMT2A (0.49) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3011781 0.86 ALDH1A1 (0.47) GBA1LMNAKMT2AMEN1MAPK1
SCHEMBL3008933 0.86 LMNA (0.44) LMNAKMT2AMEN1MAPK1ALDH1A1
SCHEMBL3007742 0.86 GBA1 (0.41) GBA1LMNAKMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GBA1 4/4885LMNA 80/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.